Arrowhead Research reported $202.25M in Cash and Equivalent for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US USD 139.26M 16.81M
Alnylam Pharmaceuticals ALNY:US USD 866.39M 206.83M
Anika Therapeutics ANIK:US USD 86.33M 1.45M
Arrowhead Research ARWR:US USD 202.25M 94.24M
Bluebird Bio BLUE:US USD 66.48M 15.02M
Heron Therapeutics HRTX:US USD 50.44M 1.83M
Intercept Pharmaceuticals ICPT:US USD 50.52M 62.68M
Ligand Pharmaceuticals LGND:US USD 211.87M 207.75M
Mirati Therapeutics MRTX:US USD 182.23M 8.69M
Moderna Inc MRNA:US USD 3.2B 178M
Nektar Therapeutics NKTR:US USD 88.23M 17.53M
Novartis NOVN:VX USD 7.52B 1.21B
Opko Health OPK:US USD 153.2M 27.64M
Sarepta Therapeutics SRPT:US USD 966.78M 71.85M
Spectrum Pharmaceuticals SPPI:US USD 56.26M 30.74M
Tg Therapeutics TGTX:US USD 102.3M 7.56M
Ultragenyx Pharmaceutical RARE:US USD 132.94M 258.71M
Vertex Pharmaceuticals VRTX:US USD 10.78B 1.61B
Xencor XNCR:US USD 53.94M 1.29M
YTE INCY:US USD 2.95B 260.8M